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oRIGINAL ARTICLE
Introduction: The optimal use of epidermal growth factor receptor 
(EGFR)-related molecular markers to prospectively identify tyrosine 
kinase inhibitor (TKI)-sensitive patients, particularly after a previous 
chemotherapy treatment, is currently under debate.
Methods: We designed a prospective phase II study to evaluate the 
activity of EGFR-TKI in four different patient groups, according to 
the combination of molecular (EGFR gene mutations, EGFR gene 
copy number and protein expression, and phosphorylated AKT 
expression, pAKT) and clinicopathological (histology and smoking 
habits) factors. Correlations between molecular alterations and clini-
cal outcome were also explored retrospectively for first-line chemo-
therapy and EGFR-TKI treatment.
Results: Patients who had progressed during or after first-line che-
motherapy were prospectively assigned to EGFR-TKI treatment as 
follows: (G1) EGFR mutation (n 5 12); (G2) highly polysomic/
amplified EGFR (n 5 18); (G3) EGFR and/or pAKT positive (n 5 
41); (G4) adenocarcinoma/bronchoalveolar carcinoma and no smok-
ing history (n 5 15). G1 and G4 had the best and second-best overall 
response rate (25% and 20%, respectively), whereas the worst out-
come was observed in G2 (oRR, 6%; p 5 0.05). Disease control 
was highest in G1 and G4 (.50%) and lowest in G3 (,20%) (p 5 
0.02). Patients selected by EGFR mutation or clinical parameters (G1 
and G4) also had significantly better progression-free survival and 
overall survival (p 5 0.02 and p 5 0.01, respectively). Multivariate 
analysis confirmed the impact of sex, smoking history, EGFR/KRAS 
mutation, and pAKT on outcomes and allowed us to derive an effi-
cient predictive model. Histology, EGFR mutations, and pAKT were 
independent predictors of response to first-line chemotherapy at ret-
rospective analysis, whereas pAKT and human epidermal growth 
factor receptor 2 expression were the only independent predictors of 
progression-free survival and overall survival.
Conclusions: Selection of patients based on either EGFR mutation 
or clinical characteristics seems an effective approach to optimize 
EGFR-TKI treatment in chemotherapy-pretreated non–small-cell 
lung cancer patients.
Key Words: Non–small-cell lung cancer, EGFR, KRAS, Tyrosine 
kinase inhibitors.
(J Thorac Oncol. 2012;7: 672–680)
L ung cancer is the leading cause of cancer deaths world-wide, regardless of sex, and has an overall 5-year survival 
rate of approximately 15%.1,2 Non–small-cell lung cancer 
(NSCLC) accounts for about 80% of all lung cancers3 and 
its dismal prognosis is heavily influenced by the fact that the 
majority of patients presents with advanced, inoperable dis-
ease at diagnosis.2,4 Although palliative chemotherapy has led 
to minimal progress in the past 10 years,4 we have recently 
witnessed a major revolution in the approach to the systemic 
treatment of advanced disease. Indeed, the introduction of 
small-molecule inhibitors of the tyrosine kinase activity of 
the epidermal growth factor receptor (EGFR-TKI)5,6 and the 
discovery of somatic, activating EGFR mutations in lung 
adenocarcinoma7,8 have opened new scenarios in the manage-
ment of inoperable NSCLC.9,10
The role of the EGFR-TKI as the best first-line thera-
peutic option for patients with advanced NSCLC harboring a 
mutated EGFR (EGFR-M1) has been firmly established by 
the retrospective analysis of EGFR-M1 patients included in 
two large phase III trials conducted in Asian patients with lung 
adenocarcinoma11,12 and by three prospective randomized trials 
selectively accruing EGFR-M1 patients.13–15 A recent meta-
analysis of these five trials conducted by our group, encom-
passing 805 Asian patients with EGFR-M1,16 unequivocally 
demonstrates EGFR-TKI superiority (approximately 25% 
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increase in progression-free survival [PFS] and overall response 
rate [oRR]), as compared to standard, platinum-based first-
line chemotherapy, with significantly less toxicity. Conversely, 
patient selection for second and subsequent lines of treatment 
with EGFR-TKI using EGFR molecular profiling (including 
mutational analysis) is more controversial.17–19 Among other 
factors, such controversy stems from the lack of evidence of a 
clear benefit from erlotinib treatment in EGFR-M1 included 
in the retrospective analysis of the BR.21 trial20 and from the 
suggestion that other subgroups of NSCLC (patients with 
EGFR gene amplification, EGFR overexpression by immuno-
histochemistry [IHC], constitutive AKT phosphorylation, etc.) 
may also derive substantial benefit from EGFR-TKI treatment. 
However, these data are mostly derived from small-scale, often 
retrospective, single-arm studies that employed individual 
selection markers, rather than comprehensive assessments of 
the EGFR molecular profile. As a result, the use of molecu-
lar selection markers other than EGFR mutation testing for 
EGFR-TKI treatment assignment remains speculative at pres-
ent, particularly for patients who have already undergone first-
line chemotherapy for advanced disease.18
We therefore set out to prospectively investigate the 
activity of EGFR-TKI as second or subsequent line treatment 
in molecularly defined subgroups of patients with advanced 
NSCLC, using three commonly used selection parameters 
(EGFR mutation, EGFR gene amplification/high-grade poly-
somy, EGFR and/or pAKT overexpression). An additional 
group of patients, in whom molecular tests were negative or 
could not be performed, was selected on the basis of purely 
clinical factors (adenocarcinoma histology and no smok-
ing history), taking into account the significant fraction of 
patients for whom adequate tissue is not obtainable in routine 
clinical practice. Finally, the impact of EGFR molecular pro-
filing on the outcome after standard first-line chemotherapy 
was also analyzed retrospectively.
PATIENTS AND METHODS
Study Design
The study was designed as a prospective phase II study 
evaluating EGFR-TKI (gefitinib—Iressa, Astrazeneca Inc., 
London, UK, or erlotinib—Tarceva, Hoffman-LaRoche, Basel, 
Switzerland) as a second or subsequent line of treatment in 
advanced NSCLC patients progressing after at least one line 
of standard chemotherapy. Patients were assigned to treatment 
according to four different clinical/pathological groups: group 
1 (G1), mutated EGFR; group 2 (G2), EGFR mutation nega-
tive or unknown, amplified EGFR gene, and/or high-grade 
chromosome no. 7 polysomy; group 3 (G3), EGFR muta-
tion/amplification negative/unknown, positive EGFR and/or 
pAKT IHC staining; group 4 (G4), molecular profile negative 
for parameters defining groups 1 to 3 or not evaluable, adeno-
carcinoma or bronchoalveolar carcinoma histology, and no 
smoking history (never smokers: ,100 cigarettes in lifetime; 
former smokers: smoking cessation 6 months before starting 
therapy). Main inclusion criteria encompassed: histologically 
or cytologically proven stage-IIIB or -IV NSCLC; at least one 
previous line of cytotoxic chemotherapy for advanced disease 
(TKI were allowed as first-line treatment for advanced disease 
for patients who progressed during or shortly [,6 months] 
after platinum-based neoadjuvant/adjuvant chemotherapy); 
Eastern Cooperative oncology Group performance status of 
0 to 2; measurable disease according to Response Evaluation 
Criteria in Solid Tumors (RECIST) criteria21; other standard 
eligibility criteria for EGFR-TKI treatment also applied. The 
study was approved by the local ethics committee. Eligible 
and consenting patients received gefitinib 250 mg/d or erlo-
tinib 150 mg/d until disease progression, unacceptable toxic-
ity, or consent withdrawal.
Sample Size Calculation and Statistical Analysis
objective response was the primary end point of the 
study; using a single-stage design as described by A’Hern,22 
a sample size of 40 patients was considered sufficient to 
yield an 80% probability (1 – ) of rejecting a baseline 
response rate of 10% (p
0
) when the true response rate was 
25% (p
1
), with an exact 5% one-sided significance test (a). 
The study was to be stopped and EGFR-TKI treatment 
rejected for that specific group if less than eight objective 
responses were observed in any of the clinical/pathological 
groups. Descriptive statistics were used to summarize perti-
nent study information. optimal cutoff values for pAKT and 
EGFR expression levels as detected by IHC were selected 
using maximally selected log-rank statistics23 (Supplemental 
Figure S1, Supplemental Digital Content 1, http://links.lww 
.com/JTo/A248). The association among genetic variables, 
biopathologic characteristics, and response/disease control 
rate (DCR) was tested by Pearson’s 2 or Fisher’s exact test, 
as appropriate. Multiple correspondence analysis (MCA), 
a descriptive/exploratory technique designed to analyze 
simple two-way and multiway tables, was used to identify 
the association of multiple variables into complex biological 
profiles. oRR, according to the RECIST criteria,21 and DCR 
(defined as the combination of patients achieving an objective 
response [oR] or disease stabilization for 6 months) were 
derived with 95% confidence intervals (CIs). Univariate and 
multivariate logistic regression analyses were used to assess 
the impact of different variables on DCR, after adjusting 
for the effect of all other variables. Results are reported as 
oR, with 95% CI. overall survival (oS, defined as the time 
between treatment start and death for any cause) and PFS 
(defined as the time between treatment start and progression 
or death for any cause) were calculated by the Kaplan-Meier 
product-limit method. The log-rank test was used to assess dif-
ferences between subgroups. Significance was defined at the 
p , 0.05 level. Hazard ratios and 95% CI were estimated for 
each variable using the Cox univariate model. A multivariate 
Cox proportional hazard model was also developed using 
stepwise regression (forward selection); enter- and remove-
limits for logistic and Cox multivariate analysis were p 5 
0.10 and p 5 0.15, respectively. A logistic equation includ-
ing the coefficients of the regression analysis was then con-
structed to calculate an estimation of individual patient’s 
probability of PFS and oS upon EGFR-TKI treatment: prob-
ability of 6-month PFS/1-year oS 5 (Exp∑(X 3 B) 1 intercept(a))/1 
1 (Exp∑(X 3 B) 1 intercept(a)), where X 3 B is the coefficient B 
for each single confounding factor X.24,25 The SPSS (version 
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17.0), R-Software (version 2.6.1), and Medcalc (version 11.0) 
statistical programs were used for all analyses.
EGFR Molecular Profiling
Genomic DNA was isolated by standard procedures. 
Genetic analysis of the EGFR gene was carried out as previously 
described26; for the detection of KRAS mutations a recently 
described mutation-enriched sequencing method was used.26,27 
EGFR fluorescence in-situ hybridization assay was carried out 
using the locus-specific identifier EGFR (Spectrum orange) 
and the chromosome enumeration probe 7 (Spectrum Green) 
probes (Vysis, Downers Grove, IL), as previously described.28 
Fluorochrome signals were captured individually and images 
were generated using the Quips Genetic Workstations and 
Imaging Software (Vysis). Slides were analyzed at 10003 
magnification. At least 100 well-defined nuclei were scored 
for each hybridization. Amplification was defined as an EGFR 
to CEP7 ratio greater than two. Polysomy levels were strati-
fied into low- and high-grade according to a recently proposed 
scoring system.29 EGFR expression was assessed by indirect 
immunoperoxidase staining using EGFR-pharmDx-kit (Dako, 
Milan, Italy). human epidermal growth factor receptor 2 
(HER-2) and phospho-AKT expression were assessed by indi-
rect immunoperoxidase staining after pretreatment of the sec-
tions in a thermostatic bath at 96°C for 40 minutes in 10-mM 
citrate buffer (pH 6). Sections were then incubated with an 
anti-HER-2 polyclonal antibody (A0485, Dako) or with two 
polyclonal antibodies against phosphorylated AKT (Ser473, 
pAKT). Immunostaining was revealed by a streptavidin- 
biotin–enhanced immunoperoxidase technique (Super 
Sensitive MultiLink, Novocastra, Menarini, Florence, Italy) 
in an automated autostainer (Bond Max, Menarini). EGFR, 
HER-2, and pAKT expression were scored considering both 
staining intensity (0, 11, 21, and 31) and percentage of 
positive cells.30 A hybrid variable was then created by multi-
plying staining intensity1–4 by the percentage of positive cells 
(0–100), as recently suggested.29 For HER-2 protein expres-
sion, we used the Herceptest scoring system and regarded 0 to 
11 cases as negative and 21 to 31 cases as positive.
RESULTS
Study Population and Molecular Analysis
From March 2005 to December 2007, 188 patients 
referred to our Institution for advanced (stage IIIB or IV), pre-
treated NSCLCs were screened for molecular alterations along 
the EGFR pathway (Fig. 1). Clinical and biological characteris-
tics are listed in Supplemental Table S1(Supplemental Digital 
Content 2, http://links.lww.com/JTo/A249). one or more of 
the planned molecular analyses could not be performed in a 
fraction of patients, ranging from 24 (not evaluable for EGFR 
amplification) to 40% or more (not evaluable for EGFR and 
KRAS mutations), because of the lack of adequate tissue sam-
pling (inadequate fixation, small biopsies, inadequate tumor 
sampling, and cytology only) or the inability to obtain paraf-
fin-embedded tumor blocks for patients referred from differ-
ent institutions. First, we explored the relationships between 
clinical/pathological and molecular parameters using MCA. 
In addition to the expected association among female sex, no 
smoking history, adenocarcinoma histology, and EGFR muta-
tions, MCA revealed a close association among EGFR, pAKT, 
and HER-2 expression, and KRAS mutations (Supplemental 
Figure S2, Supplemental Digital Content 3, http://links.lww.
com/JTo/A250); logistic regression analysis confirmed sta-
tistically significant associations between selected clinical and 
biological parameters (Supplemental Table S2, Supplemental 
Digital Content 4, http://links.lww.com/JTo/A251).
EGFR Pathway Status and Outcome after EGFR-
TKI Treatment
Upon progression after previous chemotherapy (neoad-
juvant/adjuvant: n 5 14; first line: n 5 51; second line or sub-
sequent lines: n 5 21), 86 patients were prospectively assigned 
to EGFR-TKI treatment (gefitinib: n 5 41; erlotinib: n 5 45) 
according to one of the following clinical/molecular groups: 
(G1), mutated EGFR (n 5 12); (G2), EGFR mutation negative/
unknown, amplified EGFR gene and/or high-grade chromosome 
no. 7 polysomy (n 5 18); (G3), EGFR mutation/amplification 
negative/unknown, positive EGFR and/or pAKT IHC staining 
(n 5 41); (G4), molecular profile negative or not evaluable for 
parameters defining groups 1 to 3, adenocarcinoma or broncho-
alveolar carcinoma histology and no smoking history (n 5 15) 
(Fig. 1). The presence of KRAS mutations was also analyzed in 
all patients with adequate material, but was not used as a selec-
tion criterion. oRR and DCR in the entire cohort were 12% 
(95% CI, 5–18%) and 34% (95% CI, 24–44%), respectively. 
Complete and partial responses occurred more frequently in 
G1 (oRR, 25%) and G4 (oRR, 20%), whereas G2 and G3 had 
a statistically significant worse outcome in terms of oR (p 5 
0.05). Similarly, DCR was highest in EGFR-mutated patients 
(G1: 58%) and progressively decreased in clinically selected 
(G4: 53%), EGFR-amplified/polysomic (G2: 33%), and 
EGFR/pAKT overexpressing patients (G3: 19%) (p 5 0.02, 
Fig. 2A and B). Median PFS and oS in the entire cohort were 
FIGURE 1. Study flow diagram and EGFR-TKI treatment 
allocation by molecular subgroup. NSCLC, non–small-cell 
lung cancer; EGFR, epidermal growth factor receptor; pAKT, 
phosphorylated AKT; HER-2, human epidermal growth factor 
receptor 2; IHC, immunohistochemistry; TKI, tyrosine kinase 
inhibitor.
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4 months (95% CI, 3–5 months) and 9 months (95% CI, 5–12 
months), respectively. When PFS and oS outcomes were 
analyzed according to molecular/clinical group classifica-
tion, significant differences were found (p 5 0.02 and p 5 
0.01, respectively): indeed, patients in G1 and G4 had longer 
PFS (median: 7 and 10 months, respectively), as compared to 
patients in G2 and G3 (median PFS: 5 and 4 months, respec-
tively); oS was similar in G1, G2, and G4 (median oS: 24, 18, 
and 18 months, respectively) and shorter in G3 (median oS: 
6 months) (Fig. 2C and D). Toxicity was within the expected 
range for pretreated NSCLC patients undergoing EGFR-
TKI treatment, both qualitatively and quantitatively, with 8% 
grade 3 to 4 skin toxicity, 3% grade 3 to 4 diarrhea, and 5% 
of patients who required temporary treatment interruptions 
and/or dose reductions (data not shown). To further confirm 
these results, we retrospectively analyzed the entire cohort of 
screened patients treated with EGFR-TKI, which included 13 
additional patients who did not belong to any of the abovemen-
tioned prospective groups (n 5 99). Such a retrospective anal-
ysis served two main purposes: first, the choice of prospective 
selection factors was made a priori and did not allow check-
ing for the influence of factors that could not be accounted for 
in the design of the prospective groups; second, multivariate 
analysis performed on the entire cohort of treated patients was 
also instrumental in the construction of a model for the predic-
tion of individual patient probability of outcome (see below). 
Low pAKT expression was the only independent predictor of 
better DCR at multivariate analysis (p 5 0.0005). No smoking 
history (p 5 0.006), EGFR mutations (p 5 0.091), absence of 
KRAS mutation (p 5 0.025), and low pAKT expression (p , 
0.0001) were independent predictors of longer PFS; similarly, 
when oS was considered, female sex (p 5 0.005), EGFR muta-
tions (p 5 0.062), absence of KRAS mutations (p , 0.0001), 
and low pAKT expression (p , 0.0001) were independent pre-
dictors of longer oS (Table 1 and Fig. 3). The accuracy of the 
derived, four-variable, mul tivariate models was further verified 
by receiver-operating characteristic analysis, which demon-
strated an area under the curve of 0.82 (95% CI, 0.73–0.90) 
and 0.73 (95% CI, 0.63–0.81) for PFS and oS, respectively 
(Supplemental Figure S3, Supplemental Digital Content 5, 
http://links.lww.com/JTo/A252). In addition, such multivari-
ate models were able to predict an individual patient probabil-
ity of a 6-month PFS ranging from 1.4 to 84.3% (Supplemental 
Figure S4, Supplemental Digital Content 6, http://links.lww.
com/JTo/ A253) or an individual patient probability of 1-year 
oS ranging from 8.8 to 57.5% (Fig. 4).
EGFR Pathway Status and Outcome after First-
Line Chemotherapy
one hundred forty-four patients were evaluable for clin-
ical outcome following first-line chemotherapy, which con-
sisted of platinum-based doublets in the majority of patients, 
FIGURE 2. Outcome upon EGFR-TKI treatment in prospectively selected molecular and clinical subgroups. G1: mutated EGFR; 
G2: EGFR mutation negative or unknown, amplified EGFR gene, and/or high-grade chromosome no. 7 polysomy; G3: EGFR 
mutation/amplification negative/unknown, positive EGFR and/or pAKT IHC staining; G4: molecular profile negative for param-
eters defining groups 1 to 3 or not evaluable, adenocarcinoma or bronchoalveolar carcinoma histology, and no smoking his-
tory. A, Overall response rate according to RECIST criteria. B, Disease control rate (DCR), defined as the proportion of patients 
achieving an objective response or disease stabilization for 6 months. C, Kaplan-Meier estimation of progression-free survival 
(PFS), D, Kaplan-Meier estimation of overall survival (OS). EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibi-
tor; RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; pAKT IHC phosphorylated AKT immunohis-
tochemistry; PR, partial response; SD, stable disease; PD, progressive disease. 
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and were retrospectively analyzed in relation to clinical/patho-
logical factors and molecular alterations along the EGFR path-
way (Fig. 1 and Supplemental Table S1, Supplemental Digital 
Content 2, http://links.lww.com/JTo/A249). oRR in the entire 
population was 21% (95% CI, 14–27%); multivariate analysis 
indicated squamous histology (p ≤ 0.02), EGFR mutations (p 5 
0.061), and low pAKT expression (p 5 0.056) as independent 
predictors of response to first-line treatment (Supplemental 
Table S3, Supplemental Digital Content 7, http://links.lww.
com/JTo/A254). Classification and regression tree analysis 
confirmed that the first node identifying patients at higher 
likelihood of response was squamous versus nonsquamous 
histology (oRR, 43% versus 18%); within the nonsquamous 
subgroup, EGFR-mutated patients had a better response 
(oRR, 38% versus 16%); finally, in patients without EGFR 
mutations, treatment response was better in low- versus high-
pAKT expressors (oRR, 20% versus 4%, data not shown). 
Median PFS and oS for the entire population were 6 months 
(95% CI, 5–8) and 19 months (95% CI, 14–24), respectively 
(Fig. 5). Multivariate analysis indicated HER-2 and pAKT 
overexpression as independent predictors of shorter PFS (p 
5 0.047 and p 5 0.006, respectively); the same factors were 
also independent predictors of shorter oS (p 5 0.005 and p 5 
0.001, respectively); in addition, subsequent EGFR-TKI treat-
ment positively impacted on oS (p < 0.0001) (Supplemental 
Table S3, Supplemental Digital Content 7, http://links.lww.
com/JTo/A254, and Fig. 5).
DISCUSSION
To the best of our knowledge, this is the first study 
to prospectively select pretreated NSCLC patients for 
EGFR-TKI treatment based on the four most widely used clini-
copathological predictive factors, i.e., EGFR mutation status, 
TABLE 1. Multivariate Analysis of Factors Influencing DCR, 
PFS, and OS upon TKI Treatment
Disease Control Rate OR (95% CI) p Value
pAKT (,120 vs. .120) 8.999 (1.972–41.069) 0.005
Progression-Free Survival HR (95% CI) p Value
Smoking history NA 0.023
 Current vs. never 2.232 (1.255–3.972) 0.006
 Former vs. never 1.482 (0.862–2.548) 0.155
 Current vs. former 0.664 (0.364–1.212) 0.182
EGFR mut (no vs. yes) 2.078 (0.889–4.854) 0.091
KRAS (pos vs. neg) 2.484 (1.120–5.506) 0.025
pAKT (<120 vs. >120) 3.220 (1.875–5.529) ,0.001
Overall Survival HR (95% CI) p Value
EGFR mut (no vs. yes) 2.749 (0.949–7.961) 0.062
pAKT (<120 vs. >120) 4.242 (2.230–8.072) ,0.001
Sex (male vs. female) 2.296 (1.280–4,119) 0.005
KRAS (pos vs. neg) 4.704 (2.074–10.668) ,0.001
DCR, disease control rate; PFS, progression-free survival; oS, overall survival; TKI, 
tyrosine kinase inhibitor; pAKT, phosphorylated AKT; oR, odds ratio; HR, hazard ratio; 
CI, confidence interval; mut, mutation; pos, positive; neg, negative; EGFR, epidermal 
growth factor receptor.
FIGURE 3. Kaplan-Meier survival plots for PFS (top panels) and OS (bottom panels) after epidermal growth factor receptor-
tyrosine kinase inhibitor therapy according to clinical/molecular factors found to be independent predictors of outcome at 
multivariate analysis (see also Table 1). Log-rank p values are shown for each individual panel. EGFR, epidermal growth factor 
receptor; PFS, progression-free survival; OS, overall survival; and pAKT, phosphorylated AKT.
677Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume  7, Number 4, April 2012 EGFR-TKI in Molecularly Selected NSCLC Patients
EGFR amplification/high-grade polysomy, EGFR/pAKT pro-
tein overexpression, and adenocarcinoma histology/no smok-
ing history. Based on activity and survival data obtained in 
the four prospective patient cohorts, patients harboring an 
EGFR mutation and patients with adenocarcinoma histology 
and no smoking history (G1 and G4) seem to be at highest 
likelihood of achieving prolonged disease control and survival. 
Conversely, molecular profiling of the EGFR pathway does not 
seem to influence outcome upon standard first-line chemother-
apy, with the notable exception of pAKT and HER-2 protein 
expression, which are powerful negative prognostic factors in 
the first-line setting. In addition, retrospective analysis of the 
patient cohort exposed to EGFR-TKI allowed us to derive a 
prognostic/predictive model that very efficiently discriminated 
the individual patient probability of being alive and/or pro-
gression free on the basis of a relatively simple combination 
of four clinical/molecular factors. As the use of two different 
EGFR-TKI (erlotinib and gefitinib) may have influenced the 
results obtained, we also retrospectively analyzed the potential 
impact of individual drugs on outcome in the entire cohort of 
EGFR-TKI–treated patients and found no significant associa-
tion among the use of erlotinib or gefitinib and DCR, PFS, and 
oS at univariate analysis, suggesting that the overall outcome 
was independent of the specific drug used.
Although the impact of different patient selection 
approaches on the performance of EGFR-TKI in the first-line 
setting is nowadays relatively clear (i.e., highly significant 
oRR/PFS benefit for EGFR-TKI in EGFR-M1 patients16 
and highly significant PFS/oS detriment for EGFR-TKI in 
unselected or EGFR-mutation–negative patients),11,31 the sec-
ond-line setting still represents a clinical and methodological 
challenge. Indeed, direct comparison of second-line gefitinib 
to docetaxel in unselected NSCLC populations demonstrates 
therapeutic equivalence in a recent meta-analysis phase II/III 
randomized studies and even suggests an oRR/PFS benefit 
for gefitinib in molecularly unselected patients of Asian ori-
gin.32 In contrast to the first-line setting, no prospective data 
from randomized trials conducted in selected (either on clini-
cal or molecular grounds) patient populations in second-line 
are currently available. Most of the proposed clinical/molec-
ular selection factors have been identified by retrospective 
analyses and, in the best-case scenario, have been evaluated in 
prospective, nonrandomized phase II trials.33–35 Another level 
of complexity in the interpretation of such data comes from 
the attrition rate generated by the relatively low sample avail-
ability for molecular analysis in retrospective analyses of pro-
spective trials conducted in unselected populations (e.g., only 
32% of the patients could be tested for EGFR mutations in 
the BR.21 study,19,20 and from the inconsistency in the choice 
of the comparator arm [active treatment versus placebo]). 
Although the patient-grouping scheme employed in our study 
was relatively complicated, such design was functional to the 
clear identification of individual clinical/molecular selection 
factors. Indeed, the lack of a comprehensive analysis of such 
factors (i.e., the use of single potential predictors or, at the 
opposite extreme, the use of mixed eligibility criteria) may 
have contributed to the present uncertainties in the identifi-
cation of patients who may benefit most from EGFR inhibi-
tion; this is best exemplified by the post hoc analysis of EGFR 
mutations and gene amplification data in the IPASS trial, in 
which 81% of the patients with high EGFR gene copy num-
ber also had EGFR mutations, possibly leading to the conclu-
sion that EGFR gene copy number may drive sensitivity to 
EGFR-TKI; instead, patients with EGFR mutations had a sig-
nificantly better PFS with gefitinib irrespective of EGFR gene 
copy number, whereas nonmutated patients did uniformly bet-
ter on chemotherapy in both high- and low-EGFR copy num-
ber groups.
Although excluding patients with unknown EGFR gene 
or protein status would have resulted in cleaner and easier-to-
interpret results, we elected to retain such patients in our study 
design to better reflect the “real-world” situation that clinicians 
often face in their routine practice; indeed, a relatively high 
percentage of patients (22–40% in the present series) lacks 
adequate material for one or more molecular analyses. From 
a practical standpoint, the management of such patients is an 
important clinical challenge as we have to balance the need to 
acquire all the necessary molecular information, sometimes 
repeating or performing de novo invasive and relatively risky 
procedures, with time constraints and the individual clini-
cal situation that, especially in a chemotherapy-pretreated, 
advanced NSCLC patient may not warrant an aggressive diag-
nostic approach. In such complicated cases, data obtained in 
FIGURE 4. Individual patient probability of 1-year overall 
survival according to different combinations of clinical/molec-
ular factors found to be independent predictors of outcome 
upon EGFR-TKI treatment at multivariate analysis (see also 
Table 1). Accuracy of the multivariate model used to calcu-
late individual patient probability of outcome was assessed 
by receiver-operating characteristic analysis (area under the 
curve 0.73; 95% CI, 0.63–0.81, see Supplemental Figure S3, 
Supplemental Digital Content 5, http://links.lww.com/JTO/
A252). EGFR, epidermal growth factor receptor; pAKT, phos-
phorylated AKT.
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relatively “pure” patient populations (typical of clinical trials) 
are not readily applicable. For the very same reason, although 
the results of prospective trials conducted in patients selected 
on the basis of purely clinical factors (histology, smoking his-
tory, and ethnicity) have not had a major impact as compared 
to historical data in unselected patients,36 we also elected to 
retain a group of patients selected only on clinicopathological 
grounds (G4). In such a real-world situation, our data clearly 
indicate that, when molecular analysis is not available or when 
a patient is negative for EGFR mutation, amplification, or 
IHC, the use of an EGFR-TKI is a reasonable option if the 
patient has never smoked and has adenocarcinoma histology. 
FIGURE 5. Kaplan-Meier survival plots for PFS (left column) and OS (right column) after first-line chemotherapy according 
to clinical/molecular factors found to be independent predictors of outcome at multivariate analysis (Supplemental Table S3, 
Supplemental Digital Content 7, http://links.lww.com/JTO/A254). Log-rank p values are shown for each individual panel. PFS, 
progression-free survival; OS, overall survival; HER-2, human epidermal growth factor receptor 2; pAKT, phosphorylated AKT; 
TKI, tyrosine kinase inhibitor; pos, positive; neg, negative.
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In this respect, the outcome of clinically selected patients (G4) 
is actually superimposable to that of EGFR-M1 patients.
one possible confounding factor in the interpretation 
of these results is obviously the prognostic impact that the 
molecular factors adopted for patient selection may have on 
the natural history of the disease per se, regardless of the treat-
ment employed. This is particularly true for EGFR mutations, 
which are commonly believed to portend increased sensitivity 
not only to EGFR-TKI but also to standard chemotherapy. This 
conclusion is mostly based on the retrospective analysis of the 
TRIBUTE first-line study, in which EGFR-M1 patients fared 
significantly better independently of the treatment assigned.37 
However, other lines of evidence do not support a “prognos-
tic” value of EGFR mutations: (1) EGFR mutations have no 
prognostic impact in series of NSCLC patients undergoing 
surgery (perhaps the best model to appreciate the impact of 
a molecular factor on the natural history of the disease) 38–41; 
(2) EGFR mutations were not prognostic in the placebo arm 
of the SATURN maintenance trial42; (3) although oRR was 
higher, survival outcomes were not statistically different in 
EGFR-M1 patients assigned to chemotherapy, as compared to 
EGFR-wt patients, in the IPASS trial.11 We assessed whether 
the group assignment might per se have influenced the results 
of EGFR-TKI treatment, by selecting patients with different 
prognostic characteristics independent of the treatment. When 
the group assignment was applied retrospectively to the 144 
patients treated with first-line chemotherapy, no statistically 
significant difference was found for PFS across all groups 
(Supplemental Figure S5, Supplemental Digital Content 8, 
http://links.lww.com/JTo/A255), thus suggesting the absence 
of a confounding “prognostic” effect.
Although KRAS mutations were identified in NSCLC 
tumors more than 20 years ago, we have only just begun 
to appreciate the clinical value of KRAS tumor status. The 
occurrence of KRAS mutations has been linked to resistance 
to small-molecule EGFR-TKI,27,43 whereas its relationship to 
the outcome upon treatment with anti-EGFR mAbs seems 
to differ depending on the context in which it is analyzed 
(colorectal cancer versus NSCLC). Given the lack of a con-
sensus, we elected not to use KRAS mutations for patient 
selection for EGFR-TKI treatment in this study; however, 
consistent with previous findings,19,27,43 the presence of 
KRAS mutations was a strong negative predictive factor for 
PFS and oS at multivariate analysis in our series of patients 
treated with EGFR-TKI.
Finally, multivariate analysis of the data reported 
herein allowed to derive a prognostic/predictive model that 
very efficiently discriminated the individual patient probabil-
ity of being alive and/or progression free on the basis of a 
relatively simple combination of five clinical/molecular fac-
tors. other prognostic/predictive models or risk indexes for 
EGFR-TKI have been proposed,44,45 mostly based on purely 
clinical factors, such as performance status, serum lactate 
dehydrogenase and hemoglobin levels, weight loss, response 
to prior chemotherapy, and occurrence of skin rash upon 
EGFR-TKI treatment; although the discrimination power of 
such models was good, they are more likely to reflect tumor 
burden and growth rate, rather than underlying biology, thus 
being potentially applicable to any kind of second-line or 
subsequent line treatment. Although our individual patient 
probability model obviously requires validation in larger and 
independent series, it does have several interesting features: 
(1) the only two clinical variables that entered the final model 
(sex and smoking habit) are actually independent predic-
tors of higher oRR and prolonged PFS even in the selected 
EGFR-M1 population, as demonstrated by our recent meta-
analysis16; (2) there are categories of patients with wt-EGFR 
that have an individual patient probability of survival upon 
EGFR-TKI treatment that is similar or higher to that of 
EGFR-M1 patients (e.g., females with KRAS mutations, 
wt-EGFR, and low pAKT have the slightly higher probability 
of 1-year survival as compared with males with wt-KRAS, 
EGFR-M1, and high pAKT (Fig. 4 and Supplemental Figure 
4, Supplemental Digital Content 6, http://links.lww.com/
JTo/A253), which raises interesting hypotheses for further 
biological, and possibly clinical, studies.
In summary, with all the limitations of uncontrolled, 
single-arm, phase II trials, our study in a real-world popu-
lation of patients does indicate that selection of patients for 
EGFR-TKI treatment upon progression after first-line chemo-
therapy should be based on EGFR mutation status whenever 
possible, but it can be also effectively be supported by clinical 
selection factors (adenocarcinoma histology and no smoking 
history) when mutational analysis is not available. Moreover, 
approaches to treatment personalization based on individual 
patient probability of outcome deserve further clinical investi-
gation and may shed light on the biology underlying sensitivity/ 
resistance to EGFR-TKI.
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